September 06, 2008
Home
About
Submit Press Release
PR Firms
Editors/Journalists
Search Archives
 
News Releases by Category  
News by Country  
News by MSA  
All News for Today  
Browse News by Day  
News by Trackbacks  
All Press Releases for January 5, 2006 Subscribe to this News Feed  
 

Telomolecular Corp. Appoints Rod Underhill as General Counsel

Download this press release as an Adobe PDF document.

Telomolecular appoints cofounder of MP3.com as its General Counsel.

Sacramento, CA (PRWEB) January 5, 2006 -- Telomolecular Corp. announces that lawyer, best-selling author, technology law professor and cofounder of MP3.com, Mr. Rod Underhil, has joined the Telomolecular team as General Counsel. MP3.com’s market value touched $6.9 billion on the day of its IPO.

“Telemolecular is poised to make stunning advancements in medical technology previously unseen in our lifetime,” said Underhill. “It is my belief that Telemolecular may well develop new therapies that prove to be as revolutionary as the Salk Vaccine and antibiotics were when they were first introduced. I am pleased to join the Telemolecular team as we look forward to taking further steps towards the day when we can announce significant medical breakthroughs based on Telemolecular technologies and science.”

We believe Mr. Underhill’s experience helping MP3.com to the top will strengthen and power our public market position as we prepare ourselves for an IPO. Rod’s entrepreneurial spirit and broad ranging expertise in navigating difficult waters is a tremendous asset to the firm.
According to Telomolecular CEO Matthew A. Sarad, “We believe Mr. Underhill’s experience helping MP3.com to the top will strengthen and power our public market position as we prepare ourselves for an IPO. Rod’s entrepreneurial spirit and broad ranging expertise in navigating difficult waters is a tremendous asset to the firm.”

About Telomolecular

Telomolecular Corp. was organized with the purpose of engineering a new class of drugs that deliver large-molecule proteins important in the treatment of aging and age-related disease across human cell membranes. The Corporation intends to finance research and development, and commercialize products. By combining new large-molecule delivery technologies with new protein discoveries it may be possible to lengthen chromosomal telomeres in therapeutic ways. Successful therapies based on this tactic may significantly offset, and potentially reverse, many devastating age-related diseases and perhaps address many of the symptoms and signs we recognize as human aging.

Telomolecular Investor Relations

Mr. Jeremy Jobe
Direct: 214-256-3698
Toll-Free: 877-377-7542
Fax: 916-290-0370

# # #


See the original story at: http://www.prweb.com/releases/2006/01/prweb328253.htm
Email this story to a colleague
Printer Friendly Version
Bookmark with del.icio.us
Bookmark with Y!MyWeb
Submit to Digg
Matthew Sarad
TELOMOLECULAR
916-410-8681
Email us Here

There are no multimedia files attached to this release. If this is your release you may add images or other multimedia files through your login.

If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2007, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright